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Design, Setting, and Participants: This is a retrospective cross-sectional study. We assessed the PA database established by the multicenter Japan Primary Aldosteronism Study. For comparative analysis, data were also collected from 274 patients with essential hypertension (EHT).
Main Outcome Measures:
We compared prevalences of obesity and metabolic disorders between patients with APA and patients with IHA. Comparisons with sex-, age-, and blood pressure-matched patients with EHT were also performed. Correlations between metabolic parameters and plasma aldosterone concentrations (PACs) in each subtype were analyzed.
Results: Analysis of 516 patients with APA and 1015 patients with IHA revealed PACs were significantly higher in patients with APA than patients with IHA. By contrast, after we adjusted for clinical backgrounds, the prevalence of obesity was significantly higher in patients with IHA than in patients with APA or EHT. Although the prevalences of diabetes mellitus and dyslipidemia did not significantly differ between patients with IHA and patients with APA, triglyceride and HbA1c were significantly higher in patients with IHA than in patients with APA. There was no significant correlation between metabolic parameters and PACs in either subtype.
Conclusions:
Patients with IHA tend to be obese despite lower PACs than in patients with APA. The present results suggest that obesity-related factors contribute to the pathogenesis of IHA. (J Clin Endocrinol Metab 103: 4456-4464, 2018) P rimary aldosteronism (PA) is a group of disorders in which aldosterone production is inappropriately high despite suppressed plasma renin activity (PRA). The inappropriate aldosterone production in patients with PA causes sodium retention and K + excretion, which, if prolonged and severe, may lead to hypertension and hypokalemia. The incidence of PA in patients with hypertension is thought to be 5% to 13% (1) (2) (3) . Several studies have reported that hyperaldosteronism also induces dysregulation of glucose homeostasis and metabolism. Aldosterone-induced hypokalemia impairs glucose tolerance by impairing insulin secretion (4) (5) (6) . Moreover, elevated plasma aldosterone concentration (PAC) itself reportedly impairs insulin secretion and promotes insulin resistance (7, 8) . Some reports have shown that the prevalences of diabetes mellitus (DM) and metabolic syndrome are higher among patients with PA than among those with essential hypertension (EHT) (4, 9-11); however, serum K + and PAC were not associated with higher DM prevalence in these patients with PA (11, 12) . However, a large-scale controlled cross-sectional study reported that the prevalence of glucose and lipid metabolism disorders did not differ between patients with PA and those with EHT (13) . It is therefore unclear whether metabolic parameters in patients with PA differ from those in patients with EHT. Several studies have reported a correlation between obesity and hyperaldosteronism. Women with obesity had higher circulating levels of angiotensinogen, renin, aldosterone, and angiotensin-converting enzyme than women who were lean, and weight loss caused significant decreases in aldosterone (14, 15) . Likewise, in adolescents with obesity PAC was significantly higher than in adolescents who were not obese, and weight loss caused a significant reduction in aldosterone (16) . Obesity reportedly induces production of adipocytokines such as C1q/TNF-related protein (CTRP) 1, leptin, and resistin, which elevate aldosterone via a renin-independent pathway (12, (17) (18) (19) . However, the relationship between obesity and the etiology of PA is unknown.
The etiologies of PA include two main subtypes: unilateral [aldosterone-producing adenoma (APA)] and bilateral [idiopathic hyperaldosteronism (IHA)], which account for .95% of all PA cases (1, 2) . APA is known to be caused by autonomous overproduction of aldosterone by an adenoma, whereas IHA, as its name indicates, is the hypersecretion of aldosterone due to an unknown cause; although it is often caused by hyperplasia of aldosteroneproducing cells in both adrenal glands, its etiology and pathophysiology remain unclear.
Although patients with APA tend to have lower serum K + and a higher PACs than patients with IHA, some reports indicate that the prevalences of obesity and metabolic disorders such as hyperglycemia and dyslipidemia in patients with IHA are equal to or higher than in patients with APA (3, 9, 13, 20, 21 ).
In the current study, we compared the prevalence of obesity and metabolic parameters between 516 cases of APA and 1015 of IHA. We also compared parameters in patients with APA or patients with IHA with those in age-, sex-, and blood pressure-matched EHT controls. This was the largest-scale multicenter study in the world comparing the prevalence of obesity and metabolic parameters between APA and IHA confirmed through adrenal venous sampling (AVS). Our objectives were to clarify the differences in the prevalence of obesity and metabolic disorders between APA and IHA and to shed light on the etiology of IHA.
Material and Methods

Study design and patients
This study was conducted as part of the Japan Primary Aldosteronism Study (JPAS). A nationwide PA registry has been established at 29 centers in Japan, including 15 university hospitals and 14 city hospitals. Patients with PA who were diagnosed and underwent AVS between January 2006 and October 2016 were enrolled. Patients eligible for JPAS were men and women aged 20 to 90 years. Patients who participated in the preceding West Adrenal Vein Sampling in Japan (WAVES-J) study were included (22) . Patients whom the investigators deemed unsuitable were excluded. The clinical characteristics, biochemical findings, results of confirmatory testing, imaging findings, AVS results, treatment, surgical findings, and related follow-up data were electronically collected via a web registry system. System construction, data security, and maintenance of the registered data were outsourced to EPS Corporation (Tokyo, Japan).
The JPAS was conducted with a data set valid on May 2017. Patients with available data, including clinical characteristics, biochemistry, and successful ACTH-stimulated AVS, were included. Patients with suspected autonomous cortisol secretion, defined as serum cortisol levels $3 mg/dL after 1 mg dexamethasone, were excluded (23) .
We also compared patients with PA and patients with EHT in the Kyoto Medical Center cohort. Among the 274 patients with EHT treated at the clinic of the Kyoto Medical Center between January 2006 and December 2013, 206 were enrolled and compared with patients with APA matched for age (63 years), sex, and systolic blood pressure (SBP) (65 mm Hg). In addition, 236 patients with EHT were similarly compared with matched patients with IHA.
Diagnosis of PA
The diagnosis of PA was made in accordance with guidelines from the Japan Endocrine Society and the Japan Society of Hypertension (24, 25) . PA was diagnosed based on positive case detection with a ratio of PAC (measured in pg/mL) to PRA (measured in ng/mL/h) .200 or a ratio of PAC to active renin concentration (ARC) (measured in pg/mL) .40, plus at least one positive result from confirmatory tests such as the captopril challenge test, the saline infusion test, the furosemide upright test, and the oral salt-loading test. Antihypertensive medications were usually changed to Ca 2+ channel blockers or a-adrenergic blockers, as appropriate, until the final diagnosis was made.
AVS
PA subtypes were diagnosed based on AVS, the procedures for which are described elsewhere (22) . ACTH (cosyntropin) was administered in a bolus injection, a bolus injection followed by continuous infusion, or only continuous infusion throughout the procedure. Adrenal vein cannulation was defined as successful if the selectivity index was .5 (26) . The selectivity index was defined as the ratio of the cortisol concentration in the adrenal vein to that in the inferior vena cava. The lateralized ratio (LR) was calculated by dividing the aldosterone to cortisol ratio on the dominant side by that on the nondominant side. The contralateral ratio was calculated by dividing the aldosterone to cortisol ratio on the nondominant side by that in the inferior vena cava. AVS data after ACTH stimulation were used for analysis in the current study.
Subtype diagnosis and patients in the current study
The unilateral PA subtype, or APA, was diagnosed when LR .4 and contralateral ratio ,1 (26, 27) . The bilateral PA subtype, or IHA, was diagnosed when LR ,2. When LR ranged from 2 to 4, patients were diagnosed with undetermined PA subtype and excluded from our comparative analysis. From among 2599 patients with PA who underwent AVS, 516 unilateral and 1015 bilateral patients were ultimately included in the study. The reasons for exclusion of the other 1068 patients were as follows: AVS performed without ACTH stimulation (n = 276); suspected autonomous cortisol secretion, which meant serum cortisol $ 3 mg/dL after 1 mg dexamethasone (n = 178); unsuccessful AVS, which meant a selectivity index #5 or no data on the selectivity index (n = 233); and undetermined subtype, which meant LR = 2 to 4 (n = 381).
Measurements
We collected data on age, sex, smoking habits, drinking habits, duration of hypertension, body mass index (BMI), SBP, diastolic blood pressure (DBP), and various blood tests [K + , creatinine, estimated glomerular filtration rate (eGFR), PAC, PRA, fasting blood sugar (FBS), HbA1c (NGSP), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL)]. eGFR was calculated with the following equation: eGFR (mL/min/1.73 m 2 ) = 194 3 serum creatinine 21 .094 3 age 20.287 3 0.739 (if female) (28) . We also investigated the prevalence of obesity, DM, dyslipidemia, hypokalemia, and proteinuria. According to the Guidelines for the Management of Obesity Disease 2016 in Japan, obesity was defined as a BMI $25 kg/m 2 in this study. DM was diagnosed at each institution according to the Japanese criteria for DM (fasting plasma glucose levels $126 mg/dL and HbA1c $6.5%) or current intake of antidiabetic therapy (29) . Dyslipidemia was diagnosed at each institution according to the Japanese criteria for dyslipidemia (fasting TG levels $150 mg/dL, LDL levels $140 mg/dL, or HDL levels ,40 mg/dL) or current intake of antidyslipidemic therapy (30) . Hypokalemia was considered to be present if serum K + was #3.5 mEq/L or if a patient was taking a K + supplement. Oral K + was administered if hypokalemia was present. The prevalence of proteinuria was defined as +, 2+, or 3+ protein in urinalyses.
Assay methods
PACs were measured with commercially available radioimmunoassays (SPAC-S aldosterone kits; Fuji Rebio, Co., Ltd., Tokyo, Japan) at all centers. The reference range for PACs with patients in a supine position was 30 to 159 pg/mL. PRA was measured with a radioimmunoassay or enzyme immunoassay. The reference range for PRA with patients in a supine position was 0.3 to 2.9 ng/mL/h (PRA-FR RIA kits; Fuji Rebio, Co., Ltd., Tokyo, Japan) at 16 centers, 0.2 to 2.3 ng/mL/h (PRA enzyme immunoassay kits; Yamasa, Co., Ltd., Choshi, Japan) at eight centers, and 0.2 to 2.7 ng/mL/h (PRA RIA kits; Yamasa, Co., Ltd.) at four centers. Plasma ARCs were measured by immunoradiometric assay (Renin IRMA-FR; Fuji Rebio, Co., Ltd.) at 1 center. The reference range for ARCs with patients in a supine position was 2.5 to 21.4 pg/mL.
Statistical analysis
Stata/SE version 14 software developed by LightStone ® was used for statistical analyses. All data are expressed as the mean 6 SD for normally distributed variables and as the median (25th to 75th percentile) for variables not normally distributed. Sex, obesity, smoking habits, drinking habits, history of DM, history of dyslipidemia, hypokalemia, and proteinuria were considered as binary variables. Student t test was used to compare parametric variables. The Mann-Whitney U test was used to compare nonparametric variables. Pearson
Ethics
The study was conducted according to Declaration of Helsinki Guidelines and the guidelines for clinical studies published by the Japanese Ministry of Health and Labor and was approved by the ethics committee of the National Hospital Organization Kyoto Medical Center as the project leader center and by the institutional ethics committees of the participating centers. This observational study was registered as UMIN ID 18756. The data from the JPAS and from patients with EHT at the Kyoto Medical Center were studied retrospectively. These studies were performed with an opt-out method. The opt-out option was presented on the website and as a notice in a prominent place at each center.
Results
Comparison of patients with APA and IHA
Comparisons of backgrounds and metabolic parameters between patients with APA or IHA are shown in Table 1 . There were more women among the patients with IHA than patients with APA. Significant differences were found between the two groups with respect to history of smoking, duration of hypertension, serum creatinine level, serum K + level, PRA, PAC, aldosterone/ renin ratio (ARR), and the rate of proteinuria. Age, SBP, DBP, history of drinking, and eGFR were similar between the two groups. Among the metabolic parameters, BMI, TC, TG, and HbA1c were significantly higher in patients with IHA than patients with APA. However, the prevalence of DM and dyslipidemia did not significantly differ between the two groups.
We next compared metabolic parameters between IHA and APA after separately adjusting for age, sex, blood pressure, smoking habits, drinking habits, duration of hypertension, creatinine, serum K + , PRA, PAC, and proteinuria (Table 2 ). In this logistic regression analysis, the prevalence of obesity was significantly higher among patients with IHA than patients with APA. Patients with IHA had significantly higher BMIs and TG levels and lower HDL levels than patients with APA. On the other hand, the prevalences of DM and dyslipidemia did not differ between the two groups. We also determined the Spearman rank correlation coefficients between PAC and metabolic parameters, including PRA, in patients with IHA or APA (Supplemental Table 1 ). No clinically significant correlations were found.
Comparison between patients with EHT and each subtype of PA
Comparisons of parameters between patients with APA or IHA and patients with EHT matched with respect to age, sex, and blood pressure are shown in Table 3 . BMI did not differ between patients with APA and EHT, despite the high PAC in patients with APA. On the other hand, the prevalence of obesity in patients with IHA was significantly higher than in patients with EHT. Serum K + levels tended to be lower in patients with APA or IHA than patients with EHT, although no significant differences in the prevalence of DM were detected. Nonetheless, HbA1c levels were significantly higher in patients with IHA than patients with EHT. In lipid profiles, TC was significantly higher in patients with EHT than patients with APA, and HDL levels were significantly lower in patients with APA and IHA than in patients with EHT. However, the prevalence of dyslipidemia did not significantly differ between patients with APA or IHA and patients with EHT.
Discussion
Aldosterone is associated with obesity in experimental studies. Ehrhart-Bornstein et al. (12) reported that secretory products from isolated human adipocytes stimulate aldosterone secretion from human adrenocortical cells. The candidate mediators stimulating aldosterone secretion were reported to be CTRP1, leptin, and resistin (17) (18) (19) . In addition, hyperinsulinemia and hyperleptinemia seen in obesity are reportedly contributors of sympathetic activation, and increased sympathetic nerve activity activates the renin-angiotensin-aldosterone system (31) . On the other hand, it has also been reported that aldosterone has an important role in adipose maturation (32) . Obesity is therefore thought to induce hyperaldosteronism through the actions of adipocytokines and activation of the sympathetic nervous system, whereas hyperaldosteronism is also thought to cause obesity through adipose maturation via mineralocorticoid receptor activation, thereby creating a vicious cycle.
In the current study, the prevalence of obesity was lower in patients with APA than patients with IHA, despite the lower serum K + and higher PAC in patients with APA. If aldosterone and hypokalemia were the only contributors to metabolic disorders, the prevalence of obesity, DM, and dyslipidemia among patients with APA would have been higher because of the high PAC and hypokalemia. In addition, correlation coefficients between PAC and metabolic disorders were low in patients with APA (Supplemental Table 1 ). Previous clinical studies reported that BMI, insulin resistance, and lipid profiles correlated with PAC among patients with EHT but not among patients with PA (3, 11, 21, 33, 34) . We observed that the prevalence of obesity was significantly higher in patients with IHA than patients with APA after we adjusted for clinical backgrounds including serum K + and PACs. This finding reflects the difference in the etiology of the two PA subtypes. APA is caused by a functional aldosterone-producing tumor, and its etiology is clear. The etiology of IHA is not yet well understood, however. Our data indicate that the prevalence of obesity is higher among patients with IHA than with APA or EHT, although the prevalences of DM and dyslipidemia do not differ between patients with IHA and the other groups after adjustment for other parameters. This suggests that IHA correlates more closely with obesity itself than with obesity-related hyperglycemia or hyperlipidemia.
We hypothesized that the pathogenesis of IHA is as follows. Obesity induces production of adipocytokines such as CTRP1, leptin, and resistin, which elevate aldosterone via a renin-independent pathway. The elevation of aldosterone increases the circulating plasma volume and suppresses renin activity. At the same time, obesity elevates renin activity via sympathetic nervous system activation and increased levels of renin substrates. When the former exceeds the latter, the ARR is elevated, and the IHA phenotype emerges. Several clinical studies have compared IHA and APA. Somlóová et al. (21) reported that 50 patients with IHA had significantly higher BMIs and TG levels and lower HDL levels than 50 patients with APA. They also reported that the prevalence of DM did not differ between the two groups but that the prevalence of hyperlipidemia was higher in patients with IHA than patients with APA. Likewise, Matrozova et al. (13) reported that BMIs are higher in patients with IHA than patients with APA but that the prevalence of DM did not differ between the two groups. However, a limitation to their study is that 207 of the 460 patients with PA did not undergo AVS. By contrast, Fallo et al. (9) reported that BMIs did not differ between 29 patients with APA and 56 patients with IHA, although PACs were significantly higher in patients with APA than patients with IHA. Similarly, Rossi et al. (3) reported that BMIs and PACs did not differ between 54 patients with APA and 72 patients with IHA. In the present JPAS, all patients underwent AVS, and a larger number of patients with PA were analyzed.
It has been reported that BMIs and the prevalence of DM do not significantly differ between patients with EHT and patients with APA or IHA, although the prevalence of hyperlipidemia is significantly higher in patients with EHT than patients with APA (3, 21) . In the current study, the prevalences of obesity, DM, and dyslipidemia did not differ between patients with APA and patients with EHT. In patients with APA, hyperaldosteronism causes obesity, hyperglycemia, and dyslipidemia. In EHT, the pathogenesis of which often has lifestyle elements (e.g., Na + intake), elevated blood pressure often coexists with metabolic disorders such as obesity, DM, and dyslipidemia. Consequently, the prevalences of these metabolic disorders did not differ between patients with APA and patients with EHT. Likewise, the prevalences of DM and dyslipidemia did not significantly differ between patients with IHA and patients with EHT. However, the prevalence of obesity was significantly higher in patients with IHA than patients with EHT. This was probably because, as we described, IHA would be a sequela of EHT, and the obesity may be related in the occurrence of IHA. In other words, some patients with EHT with low PRAs and high PACs may be in a transitional stage to IHA. A large-scale longitudinal study focusing on PRA, PAC, and BMI in patients with EHT will be necessary to confirm transition of EHT to IHA.
In several cases, it was noted that in patients with APA cortisol is cosecreted with aldosterone (35, 36) . In addition, Arlt et al. (37) recently reported that patients with PA had significantly higher cortisol and total glucocorticoid metabolite excretion than healthy controls. In the (38) . In Japan, the prevalence of BMI $30 kg/m 2 is only 3.7% among men and 3.3% among women (39), which is low compared with Western countries. In Asians, BMIs are generally lower than in white people, and Asians generally have a higher percentage of body fat than white people at the same BMI (40) . In addition, the odds of having hypertension, hyperglycemia, a high TG level, and a low HDL level at a BMI of 26 to 27.9 kg/m 2 were more than twice those at a BMI of 20 to 24 kg/m 2 according to the National Health and Nutrition Survey of Japan. The Japan Society for the Study of Obesity therefore defined a BMI $25 kg/m 2 as obesity in Japan, because the prevalence of a BMI $25 kg/m 2 and its influence on obesity-related complications in the Japanese are comparable to those of a BMI $30 kg/m 2 in Western countries. Therefore, because all participants in the current study were Japanese, we considered BMI $25 kg/m 2 to define obesity.
Our study has several limitations. This is a retrospective cross-sectional study. For patients with IHA, therefore, it is unknown whether obesity induces hyperaldosteronism or whether an unknown mechanism causes both hyperaldosteronism and obesity. However, judging from our results and those of others, it is clear that there is a correlation between obesity and IHA. Because we did not collect longitudinal data for weight change, we could not determine whether there was a decrease in ARR after weight loss in patients with IHA. Because waist circumference was not available in our data, we could not document the prevalence of the metabolic syndrome in our patients. Because some patients with DM or dyslipidemia were treated for these metabolic disorders, the values of FBS, HbA1c, TC, TG, LDL, and HDL did not always correctly reflect glucose tolerance and lipid profiles.
Conclusion
After adjustment for clinical backgrounds including PAC and serum K + levels, the prevalence of obesity was higher among patients with IHA than patients with APA. The prevalence of obesity was also higher among patients with IHA than patients with EHT matched with respect to age, sex, and blood pressure. Our results thus suggest there is a link between obesity and the etiology of IHA. However, a longitudinal cohort study is needed to validate the pathophysiologic significance of the present results.
